Fox Business - The Power to Prosper
Search Site

Bristol-Myers Squibb

Drugmakers under fire over off-label marketing

FBN’s Liz MacDonald says Public Citizen is urging the FDA to pull ads for five type-2 diabetes drugs over unapproved claims and off-label marketing.

Read More

  1. The health-care stocks to boost your portfolio

    Rehmann Financial Principal Joe Heider on the health-care stocks to watch.

  2. Health care sector drags on the S&P

    FBN’s Liz MacDonald with an update on stocks.

  3. Pfizer, AstraZeneca deal still alive?

    Argus Research president John Eade and JPMorgan Funds Chief Global Strategist David Kelly on whether AstraZeneca will re-engage with Pfizer.

  4. Bristol-Myers Squibb 1Q earnings

    Earnings HQ: FBN’s Lori Rothman breaks down Bristol-Myers Squibb ’s first-quarter earnings report.

  5. European shares move higher on M&A talks

    BGC Partners’ Mike Ingram with the latest on the European markets.

  6. What to expect from pharma

    Robert W. Baird & Co. senior analyst Brian Skorney on what investors can expect from pharma in the second quarter.

  7. Pfizer Could See Value in AstraZeneca Pipeline

    Pfizer may come back to bid for British drug company AstraZeneca after its reported 60 billion pound ($101 billion) takeover approach was rejected, since a deal coul...

  8. Investors: Brace for a Turbulent Second Quarter

    Fasten your seat belts. The second quarter is expected to be a bumpy ride.After a volatile first quarter for stocks that ended with the S&P 500 advancing a measly 1....

  9. GSK Stops Lung Cancer Vaccine Trial

    GlaxoSmithKline Plc (GSK) has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-g...

  10. Novo Nordisk Upgraded to 'Buy'

    Novo Nordisk (NYSE:NVO) was handed an upgrade to "buy" from "hold" on Tuesday from Austria's Erste Group, helping to boost its shares 1%.The Denmark-based drug giant...

  11. FDA Gives BMY Hep-C Drug 'Breakthrough' Status

    Bristol-Myers Squibb's (NYSE:BMY) investigational treatment for hepatitis C infection was awarded "breakthrough therapy designation" on Monday by U.S. drug regulator...

  12. AstraZeneca Says Generics to Dent '14 Profits

    AstraZeneca expects earnings to keep falling in 2014 as generic competition to its popular heartburn and ulcer drug Nexium takes a big bite out of U.S. profits from ...

  1. Polio virus being used to fight cancer?

    New York Presbyterian Hospital’s Dr. Mitchell Gaynor on testing the polio virus as a potential cancer treatment.

  2. Opportunities for investors in REITs?

    FBN’s Charles Payne, NewOak Capital President James Frischling, KPMG Chief Economist Constance Hunter, A&G Capital CIO Hilary Kramer and Penn Financial Group founder Matt McCall respond to viewers’ investing questions.

  3. Have oil prices bottomed out?

    LPL Financial Senior V.P. John Canally, Royal Oak Financial Group Managing Partner Matt Jehn and founder Mark Sebastian on the outlook for stocks and oil.

  4. Caterpillar posts 4Q earnings miss

    Earnings HQ: FBN’s Ashley Webster breaks down Caterpillar’s fourth-quarter earnings report.

  5. Bristol-Myers Squibb 4Q earnings beat expectations

    Earnings HQ: FBN’s Ashley Webster breaks down Bristol-Myers Squibb ’s fourth-quarter earnings report.

  6. Eli Lilly CEO: 2015 is a key transition year for us

    Eli Lilly CEO John Lechleiter discusses new products, 2015 outlook, its Alzheimer’s disease program and animal health division.

  7. Bristol-Myers Squibb 3Q earnings beat expectations

    Earnings HQ: FBN’s Lori Rothman beaks down Bristol-Myers Squibb ’s third-quarter earnings report.

‹ Prev12345Next ›
Freebase CC-BY
Source: Bristol-Myers Squibb on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL